Kyntra Bio, Inc. (KYNB): Total Liabilities
$115.12M
As of 2025-12-31
$109.22M
As of 2026-06-30
-42.7%
3-year compound annual growth
-21.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $115.12M | -71.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $398.16M | -32.0% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $585.73M | -4.2% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $611.57M | +12.3% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $544.71M | +41.3% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $385.39M | +19.7% | 2022-03-04, Balance as of period end |
| 2019-12-31 | $321.99M | -8.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $352.13M | +0.3% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $350.91M | n/c | 2019-02-27, Balance as of period end |
| 2016-12-31 | $294.44M | +7.6% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $273.75M | +12.7% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $242.85M | n/a | 2016-02-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $115.12M | -71.1% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $43.95M | +271.6% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $10.55M | +95.6% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $11.85M | -22.1% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $33.41M | +88.8% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $15.74M | +48.8% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $71.79M | +15.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare KYNB, FLNA, CAMP, AARD side by side · Screen every company in Pharmaceutical Preparations ↗